StreetAlpha.app
Home › Stocks › ALEC

Alector, Inc. (ALEC)

Healthcare
$2.33
▲ +1.52%
LAST CLOSE · NOV 20

Alector develops therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. It last closed at $2.33 on Nov 20, up 1.52% on the day. The next earnings report for ALEC is expected around Wed, Feb 24, 2027, after the close. For the quarter ended Sep 2026, ALEC reported EPS of $1.11 on revenue of $162.9M, with revenue up 4895.9% from a year ago. Over its last 8 reports the stock moved an average of 19.1% the session after earnings. Over the last 12 months ALEC insiders bought $0 of stock on the open market and sold $1.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is ALEC in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ALEC.

Key Stats

Last 12 months
Results
Revenue
$173.5M
+151.2% vs a year ago
Net income
$41.4M
23.9% margin
EPS (diluted)
$0.36
Free cash flow
−$150.0M
−86.5% margin
Valuation
Market cap
$347.6M
148.9M shares
P/E
6.5
Price over 12 month EPS
Price to sales
2.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$75.5M
At Sep 30
Debt
$0
At Sep 30
Shareholder equity
$116.6M
Shares outstanding
148.9M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $207.1M$207.1MFY2021FY2022: $133.6M$133.6MFY2022FY2023: $97.1M$97.1MFY2023FY2024: $100.6M$100.6MFY2024FY2025: $21.0M$21.0MFY2025

From ALEC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 24
Estimated date · After the close
Reported EPS
$1.11
Quarter ended Sep 2026
Year ago EPS
-$0.34
Same quarter last year
Revenue
$162.9M
+4895.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.01Dec '24Mar 2025: -$0.41Mar '25Jun 2025: -$0.30Jun '25Sep 2025: -$0.34Sep '25Dec 2025: -$0.34Dec '25Mar 2026: -$0.21Mar '26Jun 2026: -$0.21Jun '26Sep 2026: $1.11Sep '26Latest $1.11
Revenue by quarter
Dec 2024: $54.2MDec '24Mar 2025: $3.7MMar '25Jun 2025: $7.9MJun '25Sep 2025: $3.3MSep '25Dec 2025: $6.2MDec '25Mar 2026: $1.0MMar '26Jun 2026: $3.3MJun '26Sep 2026: $162.9MSep '26Latest $162.9M
How ALEC moved after its last 8 reports
Average move the session after a report ±19.1%
Nov 5, 2026After the close+9.6%
Oct 5, 2026Time not announced+9.9%
Aug 6, 2026After the close−2.7%
May 7, 2026After the close−13.9%
Feb 25, 2026After the close+7.1%
Oct 21, 2025After the close−49.8%
Aug 7, 2025After the close+47.3%
May 8, 2025After the close+12.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ALECStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ALEC
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ALEC

Technical Analysis

ALEC · as of the Nov 20 close · updated each morning
Uptrend

The stock is 1% above its 20 day and 11% above its 50 day average. It is 11% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 52). The nearest support is the 20 day average at $2.32, and the nearest resistance the Pivot at $2.36.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 9.3%/day
Key levels
$2.8452 week high+21.9%
$2.52Swing high (Aug 26)+8.2%
$2.45Pivot R1+5.2%
$2.36Pivot+1.3%
$2.33Last close
$2.3220 day average−0.4%
$2.30Swing low (Nov 13)−1.3%
$2.24Pivot S1−3.9%
$2.0950 day average−10.3%
$2.07200 day average−11.2%
$2.00100 day average−14.2%
$1.0952 week low−53.2%
Indicators
RSI (14)52.14Middle of its rangeNeutral
MACD0.12Below its signal lineBearish
Stochastic46.5Middle of its rangeNeutral
ADX (14)26.1Trending up
Williams %R-61.6Oversold below −80, overbought above −20Neutral
CCI (20)14.3Oversold below −100, overbought above 100Neutral
Rate of change+2.0%Change over 10 sessionsBullish
ATR (14)$0.22Typical daily range, 9.3% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ALEC

What happened before

See how ALEC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ALEC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ALEC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ALECHow many large options trades hit ALEC, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ALEC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼52 buying vs 74 selling
  • ▼Held by funds -0.6 pts
  • ▼Funds holding -4
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding137141−2.8%
In funds' top 10330.0%
Held by funds63.8%64.4%−0.6 pts
New / increased14 / 3813 / 59−27.8%
Reduced / sold out55 / 1935 / 9+68.2%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALEC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ALEC Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$1.0M18 sales · 4 insiders
2% of the selling was under pre-arranged trading plans.
2025-12 sold $220K2026-02 sold $10K2026-03 sold $263K2026-04 sold $5K2026-06 sold $228K2026-09 sold $296KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 4Grace Wong-SaradPrincipal Accounting OfficerSale9,446$2.61$25K
Sep 3Neil Lindsay BerkleyCFO & Chief Business OfficerSale29,251$2.66$78K
Sep 3Arnon RosenthalCEOSale72,606$2.66$193K
Jun 3Grace Wong-SaradPrincipal Accounting OfficerSale9,184$1.94$18K
Jun 2Neil Lindsay BerkleyCFO & Chief Business OfficerSale19,360$1.97$38K
Jun 2Arnon RosenthalCEOSale87,216$1.97$172K
Every insider buy and sale for ALEC over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ALEC insider trades →

From SEC Form 4 filings by ALEC's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALEC is in one of them and how their past ALEC trades turned out.

ALEC in the AI portfolios
Loading…

ALEC News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALEC in an article yet. Here's the latest on the wider market.

ALEC in the news

About Alector

Alector is a biotechnology company that develops treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. Its drug candidates aim to remove harmful proteins, replace missing ones, or restore normal cell function. The company also builds a proprietary technology designed to help drugs reach the brain, and it partners with drugmakers such as GSK on some programs. Based in South San Francisco, California, Alector is still testing its candidates in clinical studies.

Headquarters
South San Francisco, CA
Founded
2013